GR antagonist ORIC-101 overcomes GR-mediated resistance to the combination of AR and AKT inhibition in preclinical prostate cancer cell lines.-MedSci.cn

GR antagonist ORIC-101 overcomes GR-mediated resistance to the combination of AR and AKT inhibition in preclinical prostate cancer cell lines.

Barkund, S; Zhou, HY; Friedman, LS; Daemen, A

CANCER RESEARCH, 2021; 81 (13):

科室
- - 订阅+
  - 更多科室
工具
服务